95 reports of this reaction
3.0% of all SODIUM POLYSTYRENE SULFONATE reports
#4 most reported adverse reaction
RENAL FAILURE is the #4 most commonly reported adverse reaction for SODIUM POLYSTYRENE SULFONATE, manufactured by ANI Pharmaceuticals, Inc.. There are 95 FDA adverse event reports linking SODIUM POLYSTYRENE SULFONATE to RENAL FAILURE. This represents approximately 3.0% of all 3,148 adverse event reports for this drug.
Patients taking SODIUM POLYSTYRENE SULFONATE who experience renal failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RENAL FAILURE is a less commonly reported adverse event for SODIUM POLYSTYRENE SULFONATE, but still significant enough to appear in the safety profile.
In addition to renal failure, the following adverse reactions have been reported for SODIUM POLYSTYRENE SULFONATE:
The following drugs have also been linked to renal failure in FDA adverse event reports:
RENAL FAILURE has been reported as an adverse event in 95 FDA reports for SODIUM POLYSTYRENE SULFONATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RENAL FAILURE accounts for approximately 3.0% of all adverse event reports for SODIUM POLYSTYRENE SULFONATE, making it a notable side effect.
If you experience renal failure while taking SODIUM POLYSTYRENE SULFONATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.